The solution format enables parenteral administration routes (IV, IP, SC) not feasible with capsules, which are limited to oral delivery. For in vitro assays, direct dilution from the 5 mg/ml stock into assay medium avoids organic solvent introduction that capsule powder dissolution typically requires.

Volume-based dosing also eliminates powder weighing steps and the associated measurement error in small-dose animal studies. The capsule format is preferred for oral administration protocols where solution handling is not required.

For mitochondrial ETC Complex III bypass studies, methylene blue is typically active at nanomolar to low micromolar concentrations in cell-based assays (0.1–10 µM). At these concentrations, the redox potential of MB/MBH2 cycling enables electron shuttling between NADH/Complex I and cytochrome c, bypassing Complex III.

Importantly, MB exhibits hormetic behaviour — low concentrations are cytoprotective (ETC enhancement), while higher concentrations (>10–100 µM) can be pro-oxidant. The 5 mg/ml stock (15.6 mM) requires approximately 1,000-fold dilution for typical assay working concentrations.

Methylene Blue absorbs maximally at 664 nm and, upon irradiation at this wavelength, undergoes intersystem crossing to its excited triplet state, which transfers energy to molecular oxygen to generate singlet oxygen (¹O₂) — the primary cytotoxic species in photodynamic applications.

The solution format simplifies preparation of defined MB concentrations for photosensitisation experiments, enables even distribution in assay well plates without dissolution heterogeneity, and allows precise control of photosensitiser concentration. Irradiation source intensity, exposure duration, and MB concentration are the key experimental variables in photodynamic research protocols.